Search - tctmd.com

Displaying 441 - 460 of 622

Sort: Relevancy | Date

Presentation Fellows 2013

Drug-Eluting Stents: Past, Present, and Future

Presenter: Gregg Stone

April 15, 2013

News Daily News

Study Looks at Adding Corticosteroid Treatment to Bare-Metal Stenting

Jason Kahn

March 25, 2013

News Daily News

BIOSOLVE-1 Shows Improvement in Paclitaxel-Eluting Bioabsorbable Stent

March 25, 2013

Presentation ACC 2013

One-Year Outcome of a Trial Comparing Second Generation Drug-eluting Stents Using Either Biodegradable Polymer or Durable Polymer

Presenter: Masahiro Natsuaki

March 09, 2013

News Conference News ACC 2013

Is Nobori NEXT? Biodegradable-Polymer DES Noninferior to EES

Jason Kahn

March 09, 2013

News Daily News

ISAR-DESIRE 3 Published: Paclitaxel-Eluting Balloons Match PES for DES Restenosis

Caitlin E. Cox

February 07, 2013

Presentation TCT 2013

The longitudinal elongation of the contemporary drug eluting stent in a tapered bench-top model.

Presenter: Masaki Takenaka, Haruo Hirayama, Kenji Hurusawa, Mamoru Nanasato, Takamitu Nin, Yukihiko Yoshida, Ruka Yoshida, Hiroki Kamiya

January 31, 2013

Presentation TCT 2013

Randomized Comparison of Direct Stenting with Conventional and Provisional Stent Implantation in Elective PCI Patients Using Bare Metal and Drug Eluting Stents

Presenter: Samer Somi, Wouter Remkes, Jan-Henk Dambrink, Marcel Gosselink, Jan Hoorntje, Harry Suryapranata, Jan Paul Ottervanger, Arnoud van 't Hof

January 31, 2013

Presentation TCT 2013

Predictors of Stent Fracture and Impact on Neointimal Proliferation: Experimental Insights into the Mechanisms of Drug Eluting Stent Failure

Presenter: Seung-Jin Oh, Jong Shiuan Yeh, Piotr Buszman, Maxwell Afari, Armando Tellez, Yanping Cheng, Gerard Conditt, Jenn McGregor, Greg Kaluza, Juan Granada

January 31, 2013

Presentation TCT 2013

Intimal Hyperplasia and Vascular Remodeling after Everolimus-eluting and Sirolimus-eluting Stent Implantation in Diabetic Patients. The Randomized Diabetes and Drug-Eluting Sten...

Presenter: Lisbeth Antonsen, Lisette Okkels Jensen, Michael Maeng, Per Thayssen, Evald H?j Christiansen, Knud N?rregaard Hansen, Anne Kaltoft, Henrik Steen Hansen, Leif Thuesen, Jens Flensted Lassen

January 31, 2013

Presentation TCT 2013

Everolimus Eluting Stents Versus First Generation Drug Eluting Stents (Sirolimus or Paclitaxel) for Treatment of Drug-Eluting Stent In-Stent Restenosis

Presenter: Sachin Goel, Wael El-Mallah, Mobolaji Ige, Supriya Gupta, E Murat Tuzcu, Stephen Ellis, Samir Kapadia

January 31, 2013

Presentation TCT 2013

Efficacy and Safety of Drug-Eluting Balloon Compared to Drug-Eluting Stent for The Treatment of In-Stent Restenosis (ISR)

Presenter: Myung-Hyun Kim, Byeong-Keuk Kim

January 31, 2013

Presentation TCT 2013

Drug-eluting stent with biodegradable polymer in patients with STEMI – short and long term outcomes: data from e-NOBORI and NOBORI 2 trials

Presenter: Andres I?iguez, Farzin FATH-ORDOUBADHI, Isabel Calvo Cebollero, Albrecht Els?sser, Iskandar Atmowihardjo, Jorge Gaspar, Maciej Lesiak, Kai OPPENL?NDER, Nguyen Quang Ngoc, Ariel Roguin, Nicos Spyrou

January 31, 2013

Presentation TCT 2013

Drug Eluting Stent Fracture: Guiding the Study of Today and Tomorrow’s Stent Designs with Yesterday’s Clinical Experiences

Presenter: chad abunassar, Laura Kalvass, Santosh Prabhu

January 31, 2013

Presentation TCT 2013

Clinical Relevance of Endothelial Dysfunction after Everolimus-Eluting Stent Implantation Compared to First Generation Drug-Eluting Stent.

Presenter: Yoshifumi Nakajima, Kengo Tanabe, Jiro Aoki, Takuya Hashimoto, Kazuyuki Yahagi, Makoto Nakashima, Shuzou Tanimoto, Hiroyoshi Nakajima, Kazuhiro Hara

January 31, 2013

Presentation TCT 2013

One year clinical outcome of biodegradable and permanent polymer drug-eluting stents for multivessel disease or long lesion (?28mm) in patients with stable and unstable angina

Presenter: Jun-Won Lee, Sung Gyun Ahn, Ji-Hyun Lee, Seung-Hwan Lee, Junghan Yoon, Young-Jin Youn

January 31, 2013

Presentation TCT 2013

Late Catch-up Restenosis of Drug Eluting Stents: Evidence from Comparison with Bare Metal Stents in Japanese CAD Patients

Presenter: Yuki Horita, Masatoshi Ikeda, Isao Inoki, Masanobu Namura, Kenji Sakata, Hedenobu Terai

January 31, 2013

Presentation TCT 2013

Gender impact on patients treated with drug-eluting stents – 3 year follow-up data.

Presenter: Fazilatum Nesa Malik, William Wijns, Dezs? APR?, G?rard Finet, JACQUES MONSEGU, Damras Tresukosol, David Hildick-Smith, Ciro Indolfi, Amerigo Stabile, Gian Battista Danzi

January 31, 2013

Presentation TCT 2013

Cost Effectiveness Of Everolimus-Eluting Stents Compared To First Generation Drug-Eluting Stents In Contemporary Clinical Practice

Presenter: Robert Applegate, Matthew Sacrinty, Sanjay Gandhi, Michael Kutcher, Renato Santos, Timothy Smith, William Little

January 31, 2013

News Daily News

Ideal Duration of Dual Antiplatelet Therapy May Depend on Stent Type

Jason Kahn

January 22, 2013

Advertisement

Drug-Eluting Stents: Past, Present, and Future

Study Looks at Adding Corticosteroid Treatment to Bare-Metal Stenting

BIOSOLVE-1 Shows Improvement in Paclitaxel-Eluting Bioabsorbable Stent

One-Year Outcome of a Trial Comparing Second Generation Drug-eluting Stents Using Either Biodegradable Polymer or Durable Polymer

Is Nobori NEXT? Biodegradable-Polymer DES Noninferior to EES

ISAR-DESIRE 3 Published: Paclitaxel-Eluting Balloons Match PES for DES Restenosis

The longitudinal elongation of the contemporary drug eluting stent in a tapered bench-top model.

Randomized Comparison of Direct Stenting with Conventional and Provisional Stent Implantation in Elective PCI Patients Using Bare Metal and Drug Eluting Stents

Predictors of Stent Fracture and Impact on Neointimal Proliferation: Experimental Insights into the Mechanisms of Drug Eluting Stent Failure

Intimal Hyperplasia and Vascular Remodeling after Everolimus-eluting and Sirolimus-eluting Stent Implantation in Diabetic Patients. The Randomized Diabetes and Drug-Eluting Sten...

Everolimus Eluting Stents Versus First Generation Drug Eluting Stents (Sirolimus or Paclitaxel) for Treatment of Drug-Eluting Stent In-Stent Restenosis

Efficacy and Safety of Drug-Eluting Balloon Compared to Drug-Eluting Stent for The Treatment of In-Stent Restenosis (ISR)

Drug-eluting stent with biodegradable polymer in patients with STEMI – short and long term outcomes: data from e-NOBORI and NOBORI 2 trials

Drug Eluting Stent Fracture: Guiding the Study of Today and Tomorrow’s Stent Designs with Yesterday’s Clinical Experiences

Clinical Relevance of Endothelial Dysfunction after Everolimus-Eluting Stent Implantation Compared to First Generation Drug-Eluting Stent.

One year clinical outcome of biodegradable and permanent polymer drug-eluting stents for multivessel disease or long lesion (?28mm) in patients with stable and unstable angina

Late Catch-up Restenosis of Drug Eluting Stents: Evidence from Comparison with Bare Metal Stents in Japanese CAD Patients

Gender impact on patients treated with drug-eluting stents – 3 year follow-up data.

Cost Effectiveness Of Everolimus-Eluting Stents Compared To First Generation Drug-Eluting Stents In Contemporary Clinical Practice

Ideal Duration of Dual Antiplatelet Therapy May Depend on Stent Type

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content